249 Users Online
Bladder Cancer Treatment Drugs Market by Cancer type (Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer)
The Global Bladder Cancer Treatment Drugs Market recorded a valuation of US$ 3.04 billion in 2022 and is expected to jump to US$ 14.8 billion by the end of 2033, expanding rapidly at a CAGR of 15.6% over the next ten years. According to this new study by Persistence Market Research, North America is the leading regional market and accounted for a market share of 46.7% in 2022.
There are two types of bladder cancers. One type is where only the bladder lining is impacted by non-muscle invasive bladder cancer. It does not penetrate the innermost layer of the bladder or the deeper layer of the bladder's muscles. This illness is known as 'superficial bladder cancer'. Muscle-invasive bladder cancer is the second type where the cancerous cells have migrated into or through the muscle layer of the bladder wall. There are numerous treatment options available, including chemotherapy, surgery, and radiotherapy.
Cancer cells may stop reproducing and developing when exposed to chemotherapy (cytotoxic) drugs, which may also result in tumors becoming smaller. Drugs used to kill cancer cells are known as cytotoxic medicines or cytostatic (also known as cytotoxic chemotherapy). With the advancement of pharmacological therapy, the importance of cytotoxic medications in cancer treatment has marginally decreased.
Cancer immunotherapy, commonly referred to as immuno-oncology, is a type of cancer treatment that takes advantage of the immune system's capacity to stop, manage, and eradicate cancer. Targeted antibodies, cancer vaccines, adoptive cell transfer, tumor-infecting viruses, checkpoint inhibitors, cytokines, and adjuvants are a few of the different forms it might take. When components from live organisms are employed to treat the condition, it is known as a biological treatment.
Targeted therapy is a sort of treatment that targets particular cancer cell types with medications or other substances while causing the least amount of damage to healthy cells. Some proteins, enzymes, or other substances involved in the growth and spread of cancer cells are blocked by several targeted therapies.
Bladder Cancer Treatment Drugs Market Size (2022) |
US$ 3.04 Billion |
Estimated Market Value (2023) |
US$ 3.49 Billion |
Forecasted Market Value (2033) |
US$ 14.8 Billion |
Global Market Growth Rate (2023 to 2033) |
15.6% CAGR |
Market Share of Top 5 Countries |
66.5% |
“Increased Financing for Research and Growing Clinical Studies for Cancer”
The global market expanded at a CAGR of 16.6% from 2012 to 2022 mainly due to a boost in cancer research funding.
As a result of increased financing for cancer research, the quality of life for cancer patients has improved significantly and patient survival rates have significantly risen.
The National Cancer Institute (NCI) offers funding for research projects in fields where the commercial sector lacks interest, including ground-breaking basic research and projects on cancer screening, prevention, and rare malignancies.
The National Institutes for Health (NIH) in the United States is the largest public supporter of biomedical research in the entire globe. The United States is now a global leader in the development of cancer medicines and diagnostic techniques because of NIH-funded research that has spurred discoveries that businesses rely on to bring novel cancer medications to market.
Clinical studies are carried out by the NCI on cancer patients whose prognosis requires several diagnoses. Companies are encouraged to perform more research on cancer diagnosis and therapy when there is more funding for the same.
One-third of all fatalities are attributable to the primary behavioral and dietary risk factors for death: high body mass index, inadequate intake of fruits and vegetables, lack of physical exercise, and excessive tobacco and alcohol consumption.
Cancer mortality rates are continuing to decrease as a result of screening for some cancers, including breast, cervical, colon, prostate, rectal, and more recently, lung cancer, as well as the availability of combination therapies for many cancers and the use of chemotherapy after surgery for breast and colon cancer.
Owing to the factors mentioned above, the global bladder cancer treatment drugs market is forecasted to surge ahead at a CAGR of 15.6% during the forecast period (2023 to 2033).
“Switching to Molecularly Targeted Medications or Immunotherapies”
The idea of switching to molecularly targeted medications or immunotherapies instead of conventional chemotherapy, which has historically been the basis of first-line treatment for advanced malignancies, has many appeals because they promise improved efficacy and enhanced quality of life.
In the next ten years, some estimates claim that the market for immunotherapy as a whole might represent 30% to 40% of the market for oncology medicines. This prediction becomes more realistic with each regulatory permission that major businesses in this sector acquire.
“High Cost for Drug Development and Lack of Availability of Cancer Medications in Underdeveloped & Emerging Nations”
Since it takes a long time and costs a lot of money, drug development is not easy. As it typically takes 10 years from synthesis to approval and 88% of medications are refused, studying the drug to ascertain its efficacy and safety comes at a significant cost. Drug duplication is another obstacle to the market.
The fact that a majority of important cancer medications are not available in underdeveloped and emerging nations is one of the main issues restricting the growth of the worldwide market for pharmaceuticals to treat bladder cancer.
A majority of the world's countries lack access to pharmaceuticals because their makers either failed to obtain regulatory permission, their approval was delayed or denied, or their manufacturers were waiting for the outcome of reimbursement negotiations before releasing the drug there. Most new pharmaceutical markets allegedly have less than 20% of cancer medications available.
Several factors, including a deficient healthcare system, inadequate infrastructure, and additional obstacles such as fragmented diagnostic environments, a shortage of or unequal distribution of healthcare workers, and numerous logistical and financial challenges such as high costs, lack of quality assurance, frequent stock-outs, and difficult regulatory pathways, cause this.
Why is the United States a Large Market for Bladder Cancer Treatment Drugs?
“High Spending on Cancer-Related Medical Treatment”
The United States held 43% share of the global market in 2022. Rising cancer treatment spending is the chief driver for this market.
How is the United Kingdom Market for Bladder Cancer Treatment Drugs Evolving?
“Expansion of Cancer Therapy Options”
The United Kingdom accounted for 4.4% share of the global market for bladder cancer treatment drugs in 2022.
Market growth is attributed to the expansion of cancer therapy options. There are numerous cutting-edge cancer treatments available all over the world. In addition, the drive for innovation in cancer treatments is being monitored by academic institutions, biopharmaceutical firms, and healthcare system stakeholders.
Which Type of Cancer Accounts for High Demand for These Drugs?
“Non-Muscle-Invasive Bladder Cancer Accounts for Huge Market Share”
Drugs used for non-muscle-invasive bladder cancer generated revenue worth US$ 2.15 billion in 2022, with the segment projected to expand at a CAGR of 14.8% during the forecast period owing to the high rates of recurrence and risk of progression.
According to a 2019 article from the World Journal of Oncology, 70% to 75% of all cancers are non-muscle-invasive. This is the initial type before progressing to muscle invasion. Healthcare professionals focus on destroying cancer before it penetrates the muscles; hence the higher adoption.
Will Low-Grade Bladder Cancer Continue Accounting for High Demand for Drug Treatment?
“Lower Risk of Recurrence after Drug-related Treatment”
Low-grade bladder cancer accounted for a market revenue share of 69.8% in 2022. Low-grade bladder cancers are mostly on the bladder surface, rarely spread or metastasize, and also have a lower risk of recurrence after treatment. When tumors have been surgically removed, drug cleansing of the bladder may lower the likelihood of cancer returning.
The global market is consolidated with a limited number of key players. Considering the competition from local players, key market players in the industry are focusing on acquiring such competitors to reach a large customer base, along with expanding into newer markets. Manufacturers are also coming up with innovative products, most of which are currently in the pipeline.
Attribute |
Details |
Forecast Period |
2023 to 2033 |
Historical Data Available for |
2012 to 2022 |
Market Analysis |
US$ Million for Value |
Key Regions Covered |
|
Key Countries Covered |
|
Key Market Segments Covered |
|
Key Companies Profiled |
|
Pricing |
Available upon Request |
By Cancer Type:
By Cancer Grade:
By Drug Type:
By Distribution Channel:
By Region:
The global bladder cancer treatment drugs market reached US$ 3.04 billion in 2022 and is set to expand 4.2X over the next ten years.
Sales of bladder cancer treatment drugs are expected to reach US$ 14.8 billion by the end of 2033.
Rise in pipeline products, co-development of companion diagnostics & predictive biomarkers, and rising approvals of novel drugs are some of the key trends in this market.
The U.S., Germany, the U.K., Canada, and France are expected to account for the most demand for bladder cancer treatment drugs.
The U.S. accounted for 92% share of the North American market in 2022.
Demand for bladder cancer treatment medicines in Europe is set to increase at 13.7% CAGR over the next ten years.
The U.S., Germany, and India are leading manufacturers of bladder cancer treatment drugs.